Literature DB >> 18411420

The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Petr O Ilyinskii1, Anatoli B Meriin, Vladimir L Gabai, Evgeny V Usachev, Alexei G Prilipov, Galini Thoidis, Alexander M Shneider.   

Abstract

It is assumed that the proteosome-processing characteristics of fusion constructs can be predicted from the sum of the proteosome sensitivity of their components. In the present study, we observed that a fusion construct consisting of proteosome-degradable proteins does not necessarily result in a proteosome-degradable chimera. Conversely, fusion of proteosome-resistant proteins may result in a proteosome-degradable composite. We previously demonstrated that conserved influenza proteins can be unified into a single fusion antigen that is protective, and that vaccination with combinations of proteosome-resistant and proteosome-degradable antigens resulted in an augmented T-cell response. In the present study we constructed proteosome-degradable mutants of conserved influenza proteins NP, M1, NS1, and M2. These were then fused into multipartite proteins in different positions. The stability and degradation profiles of these fusion constructs were demonstrated to depend on the relative position of the individual proteins within the chimeric molecule. Combining unstable sequences of either NP and M1 or NS1 and M2 resulted in either rapidly proteosome degraded or proteosome-resistant bipartite fusion mutants. However, further unification of the proteosome-degradable forms into a single four-partite fusion molecule resulted in relatively stable chimeric proteins. Conversely, the addition of proteosome-resistant wild-type M2 to proteosome-resistant NP-M1-NS1 fusion protein lead to the decreased stability of the resulting four-partite multigene products, which in one case was clearly proteosome dependent. Additionally, a highly destabilized form of M1 failed to destabilize the wild-type NP. Collectively, we did not observe any additive effect leading to proteosomal degradation/nondegradation of a multigene construct.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411420      PMCID: PMC2386737          DOI: 10.1110/ps.083443908

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  40 in total

1.  Universal influenza A vaccine: optimization of M2-based constructs.

Authors:  Marina De Filette; Willy Min Jou; Ashley Birkett; Katie Lyons; Brian Schultz; Anne Tonkyro; Stephanie Resch; Walter Fiers
Journal:  Virology       Date:  2005-06-20       Impact factor: 3.616

Review 2.  Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy.

Authors:  A L Goldberg
Journal:  Biochem Soc Trans       Date:  2007-02       Impact factor: 5.407

Review 3.  Requirements for CD8 T-cell priming, memory generation and maintenance.

Authors:  Martin Prlic; Matthew A Williams; Michael J Bevan
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

4.  Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes.

Authors:  Gregory A Stoloff; Wilson Caparros-Wanderley
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

5.  Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

Authors:  Marina De Filette; Walter Fiers; Wouter Martens; Ashley Birkett; Anna Ramne; Björn Löwenadler; Nils Lycke; Willy Min Jou; Xavier Saelens
Journal:  Vaccine       Date:  2006-06-12       Impact factor: 3.641

6.  HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1.

Authors:  Elizaveta Starodubova; Andreas Boberg; Elena V Kashuba; Britta Wahren; Vadim Karpov; Maria Isaguliants
Journal:  Vaccine       Date:  2005-08-18       Impact factor: 3.641

7.  The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA.

Authors:  Qiaozhen Ye; Robert M Krug; Yizhi Jane Tao
Journal:  Nature       Date:  2006-12-06       Impact factor: 49.962

8.  Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity.

Authors:  Petr O Ilyinskii; Vladimir L Gabai; Shamil R Sunyaev; Galini Thoidis; Alexander M Shneider
Journal:  Cell Cycle       Date:  2007-06-12       Impact factor: 4.534

9.  Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Authors:  Stephen Mark Tompkins; Zi-Shan Zhao; Chia-Yun Lo; Julia A Misplon; Teresa Liu; Zhiping Ye; Robert J Hogan; Zhengqi Wu; Kimberly A Benton; Terrence M Tumpey; Suzanne L Epstein
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  Identification of the domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization and incorporation into virions.

Authors:  Sarah L Noton; Elizabeth Medcalf; Dawn Fisher; Anne E Mullin; Debra Elton; Paul Digard
Journal:  J Gen Virol       Date:  2007-08       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.